🔎 Trials Near Me

Início › Câncer de Estômago › Michigan

Ensaios clínicos de Câncer de Estômago em Michigan

35 estudos para Câncer de Estômago estão buscando participantes em locais em Michigan.

Cidades em Michigan

Texto oficial do estudo (Inglês)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
  • e mais 50
RecrutandoVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07283939

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • e mais 68
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06760819

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  • Henry Ford Health, Detroit
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07700979

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  • Research Site, North Shores
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07069712

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Grand Rapids
RecrutandoFase 2
Idades de 18 a 130 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05489211

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • START Midwest, Grand Rapids
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Barbara Ann Karmanos Cancer Institute, Detroit
  • BAMF Health Inc., Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Barbara Ann Karmanos Cancer Institute, Detroit
  • BAMF Health Inc., Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • START Midwest, Grand Rapids
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05267626

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • University of Michigan, Ann Arbor
  • Henry Ford Cancer Institute, Detroit
  • START - Midwest Cancer Research Center, Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06253871

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Grand Rapids
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT07431281

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • e mais 13
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • Brigitte Harris Cancer Pavilion BHCP, Detroit
  • START Midwest, LLC, Grand Rapids
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07070232

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  • Research Site, Grand Rapids
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07115043

A Study of MGC026 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT05592626

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  • University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT06731478

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT04198766

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #120, Detroit
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jul. de 2026 · NCT06974110

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
  • Karmanos Cancer Institute, Farmington Hills
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT05208762

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • START Midwest, Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT06131840

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Henry Ford Health System, Detroit
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jul. de 2026 · NCT06657144

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

  • University of Michigan Rogel Cancer Center, Ann Arbor
RecrutandoFase 4
Idades 18 e acima · Mulheres · Atualizado em 2 de jul. de 2026 · NCT05183126

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

  • START Midwest /ID# 248685, Grand Rapids
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT05005403

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

  • BAMF Health, Grand Rapids
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de jun. de 2026 · NCT07219238

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

  • University of Michigan, Ann Arbor
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jun. de 2026 · NCT05768932

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Research Site, Grand Rapids
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de mai. de 2026 · NCT05702229

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

  • Henry Ford Cancer-Detroit, Detroit
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 19 de dez. de 2025 · NCT06065371

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

  • START Midwest, Grand Rapids
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de dez. de 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Ann Arbor
  • Massive Bio SYNERGY-AI site, Lansing
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

  • University of Michigan, Ann Arbor
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2025 · NCT05941507

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

  • BAMF Health, Inc., Grand Rapids
RecrutandoFase 1/2
Idades 15 e acima · Todos os sexos · Atualizado em 12 de ago. de 2025 · NCT06298916

A Beta-only IL-2 ImmunoTherapY Study

  • Karmanos Cancer Institute, Detroit
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 9 de jul. de 2025 · NCT05086692

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.